Advertisement
U.S. markets open in 2 hours 1 minute
  • S&P Futures

    5,305.50
    -2.75 (-0.05%)
     
  • Dow Futures

    40,138.00
    -6.00 (-0.01%)
     
  • Nasdaq Futures

    18,488.75
    -15.00 (-0.08%)
     
  • Russell 2000 Futures

    2,139.30
    +0.90 (+0.04%)
     
  • Crude Oil

    82.43
    +1.08 (+1.33%)
     
  • Gold

    2,232.60
    +19.90 (+0.90%)
     
  • Silver

    24.74
    -0.01 (-0.05%)
     
  • EUR/USD

    1.0797
    -0.0033 (-0.30%)
     
  • 10-Yr Bond

    4.1960
    0.0000 (0.00%)
     
  • Vix

    12.99
    +0.21 (+1.64%)
     
  • dólar/libra

    1.2625
    -0.0013 (-0.11%)
     
  • USD/JPY

    151.3700
    +0.1240 (+0.08%)
     
  • Bitcoin USD

    70,737.48
    +666.62 (+0.95%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,956.66
    +24.68 (+0.31%)
     
  • Nikkei 225

    40,168.07
    -594.66 (-1.46%)
     

Today's Research Reports on Biotech Stocks to Watch: BioCryst Pharmaceuticals and Keryx Biopharmaceuticals

NEW YORK, NY / ACCESSWIRE / May 5, 2017 / Keryx Biopharmaceuticals, who focuses on innovative medicines for people with renal disease, saw positive gains yesterday after reporting higher revenues than expected with help from the company's Auryxia drug which saw sales of $10.5 million in Q1 compared to $5.6 million a year earlier. Auryxia is given to patients who have chronic kidney disease who are on dialysis. BioCryst shares fell deep into the red despite beating Street estimates for its first quarter earnings.

RDI Initiates Coverage on:

BioCryst Pharmaceuticals, Inc.
https://ub.rdinvesting.com/news/?ticker=BCRX

Keryx Biopharmaceuticals, Inc.
https://ub.rdinvesting.com/news/?ticker=KERX

BioCryst shares fell 10.59% yesterday even though the company beat on both the top and bottom line with its Q1 report. The North-Carolina based company posted a loss of 19 cents per share for the quarter which was ahead of the 20 cents per share that five analysts surveyed by Zacks had expected. Revenue at $9.4 million also came ahead of the $5.9 million that four analysts surveyed by Zacks had been looking for. So why the drop? The drug-maker did post a loss of $14.2 million for the quarter. Despite the drop yesterday, shares of BioCryst have soared 100% in the last twelve months.

Access RDI's BioCryst Pharmaceuticals Research Report at:
https://ub.rdinvesting.com/news/?ticker=BCRX

Keryx Biopharmaceuticals, Inc. shares closed up 6.56% on Thursday despite the company reported a loss in the first quarter ended March 31, 2017. Keryx reported first quarter earnings ahead of the bell yesterday. The Boston pharma company posted a loss of 21 cents, which came in four cents higher than the 18 cent average that five analysts surveyed by Zacks Investment Research had looked for. Revenues totaled $11.8 million for the first quarter of 2017, higher than the $10.1 million that three analysts surveyed by Zacks had looked for. CEO Greg Madison commented, "In the first quarter, prescription growth continued across the dialysis patient population, with strong demand from both new patients and patients who have switched from another phosphate binder. We believe with more physicians gaining clinical experience, strong brand awareness, and broad patient access, we will bring this medicine to many more people with hyperphosphatemia on dialysis." The stock has increased almost 15% in the last 12 months.

Access RDI's Keryx Biopharmaceuticals Research Report at:
https://ub.rdinvesting.com/news/?ticker=KERX

Our Actionable Research on BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) and Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Nadia Noorani, CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

Advertisement